Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Immune checkpoint inhibitors vs any first‐line chemotherapy

Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer

Immune checkpoint inhibitors probably leads to lower adverse events grade 3 to 5 Range of compared with any first‐line chemotherapy (moderate certainty).

1 finding from 1 review

Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
RR 0.47 [0.29, 0.75]
3 studies · 2046 participants
Moderate

Immune checkpoint inhibitors vs any second‐line chemotherapy

Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer

Immune checkpoint inhibitors may leads to lower adverse events grade 3 to 5 Range of compared with any second‐line chemotherapy (low certainty).

1 finding from 1 review

Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
RR 0.89 [0.81, 0.97]
2 studies · 1423 participants
Low